Neel S. Bhatt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neel S. Bhatt has a total of 657 co-authors. Here are the top co-authors by number of shared publications:
- Akshay Sharma
Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children’s Research Hospital, Memphis, USA
12 shared publications Minoo Battiwalla
Sarah Cannon Blood Cancer Network, Nashville, Tennessee
10 shared publicationsRuta Brazauskas
Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
10 shared publicationsBronwen E. Shaw
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
9 shared publicationsMichael Byrne
Vanderbilt University Medical Center, Nashville, Tennessee
8 shared publicationsNosha Farhadfar
Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida
8 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by American Society of Hematology in Blood Advances
Maintenance ALK inhibitor after hematopoietic cell transplantation in patients with anaplastic large cell lymphoma
- 21 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessMaintenance ALK inhibitor after hematopoietic cell transplantation in patients with anaplastic large cell lymphoma
- Open Access
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2615527
Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors
Importance: The association between medical financial hardship and nonadherence to healthy lifestyle and late-effects surveillance recommendations in long-term survivors of childhood cancer is unknown. Objective: To study the associations between medical financial hardship and nonadherence to healthy lifestyle and late-effects surveillance recommendations. Design, Setting, and Participants: This retrospective cohort study was performed among participants in the multiinstitutional Childhood Cancer Survivor Study. Participants were 5-year cancer survivors diagnosed at age 21 years or younger between January 1, 1970, and December 31, 1999, and who completed both a medical financial hardship survey between 2017 and 2019 and a follow-up survey assessing lifestyle behaviors and adherence to risk-based surveillance between 2020 and 2022. Data were analyzed between September 29, 2023, and September 2, 2025. Exposure: Self-reported medical financial hardship determined by an affirmative response to at least 1 item in the material, behavioral, or psychological domains. Main Outcomes and Measures: Associations of non–guideline-concordant physical activity, problematic drinking, smoking, and abnormal body mass index with domains of medical hardship were examined using separate multivariable logistic regression models. Associations between a composite lifestyle score (unhealthy, moderately healthy, and healthy) and nonadherence to surveillance for cardiomyopathy or breast, colorectal, cervical, and/or skin cancer were examined using polytomous logistic regression models. Results: Among 3322 survivors who completed both surveys (median [range] age, 41 [20-69] years; 1751 female [52.7%]), the presence of material, behavioral, and psychological hardship was reported by 1401 (42.2%), 1003 (30.2%), and 1243 (37.4%), respectively. Material hardship was associated with a greater odds of non–guideline-concordant physical activity (odds ratio [OR], 1.67 [95% CI, 1.29-2.18]) and abnormal body mass index (OR, 1.47 [95% CI, 1.15-1.88]). Behavioral and psychological hardships were associated with a higher odds of smoking (OR, 2.29 [95% CI, 1.13-4.62] and 3.95 [95% CI, 2.42-6.44], respectively). Material and psychological hardship were associated with a composite unhealthy lifestyle score (OR, 1.52 [95% CI, 1.11-2.07] and 1.96 [95% CI, 1.31-2.93], respectively), and a higher risk was noted among survivors reporting hardship in at least 2 domains. Psychological hardship was associated with greater nonadherence to skin cancer surveillance (OR, 1.78 [95% CI, 1.05-3.02]) among survivors at high risk due to treatment exposures. Material hardship was associated with greater nonadherence to breast cancer screening (OR, 2.85 [95% CI, 1.27-6.38]) among survivors at average risk. Associations between multiple medical hardship domains and nonadherence to cervical cancer screening were also observed (material and behavioral hardship: OR, 3.20 [95% CI, 1.44-7.14]; material and psychological hardship: OR, 2.18 [95% CI, 1.10-4.35]; behavioral and psychological hardship: OR, 3.25 [95% CI, 1.50-7.04]). Conclusions and Relevance: This cohort study of adult survivors of childhood cancer found that medical financial hardship was associated with nonadherence to healthy lifestyle behaviors and certain recommended surveillance tests for subsequent malignant neoplasms. These findings underscore the need to identify and address medical financial hardship as a potential risk factor of nonadherence to healthy lifestyle and guideline-concordant survivorship care.
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2615527
Open AccessFinancial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors
Importance: The association between medical financial hardship and nonadherence to healthy lifestyle and late-effects surveillance recommendations in long-term survivors of childhood cancer is unknown. Objective: To study the associations between medical financial hardship and nonadherence to healthy lifestyle and late-effects surveillance recommendations. Design, Setting, and Participants: This retrospective cohort study was performed among participants in the multiinstitutional Childhood Cancer Survivor Study. Participants were 5-year cancer survivors diagnosed at age 21 years or younger between January 1, 1970, and December 31, 1999, and who completed both a medical financial hardship survey between 2017 and 2019 and a follow-up survey assessing lifestyle behaviors and adherence to risk-based surveillance between 2020 and 2022. Data were analyzed between September 29, 2023, and September 2, 2025. Exposure: Self-reported medical financial hardship determined by an affirmative response to at least 1 item in the material, behavioral, or psychological domains. Main Outcomes and Measures: Associations of non–guideline-concordant physical activity, problematic drinking, smoking, and abnormal body mass index with domains of medical hardship were examined using separate multivariable logistic regression models. Associations between a composite lifestyle score (unhealthy, moderately healthy, and healthy) and nonadherence to surveillance for cardiomyopathy or breast, colorectal, cervical, and/or skin cancer were examined using polytomous logistic regression models. Results: Among 3322 survivors who completed both surveys (median [range] age, 41 [20-69] years; 1751 female [52.7%]), the presence of material, behavioral, and psychological hardship was reported by 1401 (42.2%), 1003 (30.2%), and 1243 (37.4%), respectively. Material hardship was associated with a greater odds of non–guideline-concordant physical activity (odds ratio [OR], 1.67 [95% CI, 1.29-2.18]) and abnormal body mass index (OR, 1.47 [95% CI, 1.15-1.88]). Behavioral and psychological hardships were associated with a higher odds of smoking (OR, 2.29 [95% CI, 1.13-4.62] and 3.95 [95% CI, 2.42-6.44], respectively). Material and psychological hardship were associated with a composite unhealthy lifestyle score (OR, 1.52 [95% CI, 1.11-2.07] and 1.96 [95% CI, 1.31-2.93], respectively), and a higher risk was noted among survivors reporting hardship in at least 2 domains. Psychological hardship was associated with greater nonadherence to skin cancer surveillance (OR, 1.78 [95% CI, 1.05-3.02]) among survivors at high risk due to treatment exposures. Material hardship was associated with greater nonadherence to breast cancer screening (OR, 2.85 [95% CI, 1.27-6.38]) among survivors at average risk. Associations between multiple medical hardship domains and nonadherence to cervical cancer screening were also observed (material and behavioral hardship: OR, 3.20 [95% CI, 1.44-7.14]; material and psychological hardship: OR, 2.18 [95% CI, 1.10-4.35]; behavioral and psychological hardship: OR, 3.25 [95% CI, 1.50-7.04]). Conclusions and Relevance: This cohort study of adult survivors of childhood cancer found that medical financial hardship was associated with nonadherence to healthy lifestyle behaviors and certain recommended surveillance tests for subsequent malignant neoplasms. These findings underscore the need to identify and address medical financial hardship as a potential risk factor of nonadherence to healthy lifestyle and guideline-concordant survivorship care.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (5) , 844-851
Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation
PURPOSE: Public reporting of health care outcomes can have unintended effects such as inappropriate risk aversion in patient selection. METHODS: The center-specific survival analysis annually assigns all hematopoietic cell transplantation (HCT) centers in the United States a +1, −1, or 0 score for observed outcomes that are above, below, or within a center-specific predicted range of outcome. For each index year (2012-2016), centers receiving a −1 score after 0 scores in the preceding 2 years were compared with contemporaneous centers with as-predicted outcomes (0 score). Changes in the patient population characteristics in the 3 years before versus the 3 years after the index years were compared between the newly below-expected centers (NBCs) and the controls. A multivariate model adjusted for baseline patient population characteristics and center volume. RESULTS: No differences in patient selection behavior were identified when comparing the NBCs with the controls across eight key patient population characteristics. For the statistically modeled (predicted) 1-year overall survival (OS), reflecting a holistic measure of centers' patient population risk, we observed no statistically significant difference in change (−0.23% [95% CI, −1.4 to 0.9]; P = .70). The observed OS increased in both NBCs and controls by 0.9% and 4.5%, respectively, without statistically significant difference in change. CONCLUSION: Centers receiving a −1 score were not observed to deviate significantly from patient selection trends in the HCT field. These findings suggest that public reporting of HCT outcomes in the United States does not result in unintended bias against HCT for high-risk patients.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (5) , 844-851
Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation
PURPOSE: Public reporting of health care outcomes can have unintended effects such as inappropriate risk aversion in patient selection. METHODS: The center-specific survival analysis annually assigns all hematopoietic cell transplantation (HCT) centers in the United States a +1, −1, or 0 score for observed outcomes that are above, below, or within a center-specific predicted range of outcome. For each index year (2012-2016), centers receiving a −1 score after 0 scores in the preceding 2 years were compared with contemporaneous centers with as-predicted outcomes (0 score). Changes in the patient population characteristics in the 3 years before versus the 3 years after the index years were compared between the newly below-expected centers (NBCs) and the controls. A multivariate model adjusted for baseline patient population characteristics and center volume. RESULTS: No differences in patient selection behavior were identified when comparing the NBCs with the controls across eight key patient population characteristics. For the statistically modeled (predicted) 1-year overall survival (OS), reflecting a holistic measure of centers' patient population risk, we observed no statistically significant difference in change (−0.23% [95% CI, −1.4 to 0.9]; P = .70). The observed OS increased in both NBCs and controls by 0.9% and 4.5%, respectively, without statistically significant difference in change. CONCLUSION: Centers receiving a −1 score were not observed to deviate significantly from patient selection trends in the HCT field. These findings suggest that public reporting of HCT outcomes in the United States does not result in unintended bias against HCT for high-risk patients.
- Open Access
- 24 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2108-2121
Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients
Advances in graft-versus-host disease (GVHD) prevention and treatment have resulted in expanded donor options and improvement in treatment-related mortality (TRM). This analysis aimed to compare the incidence of acute and chronic GVHD (aGVHD and cGVHD, respectively) in pediatric patients by recipient age and to evaluate the impact of GVHD on overall survival (OS) and TRM. We included 14 099 patients aged ≤21 years who received their first allogeneic hematopoietic cell transplantation from 2002 to 2020, categorizing recipient age as 0 to 2 years (infants/toddlers), 3 to 12 years (school-aged), and 13 to 21 years (adolescent/young adult). There was no difference in grade 2 to 4 and 3 to 4 aGVHD by day 100 among age groups, except among patients with nonmalignant disease (NMD), among whom there was a small increase in incidence of severe aGVHD in older patients. Incidence of moderate/severe cGVHD by 1 year was higher with age. A similar impact of age was observed after adjusting for patient, donor, and transplant characteristics. Risk of severe aGVHD was higher in older children with NMD. Severe aGVHD and moderate/severe cGVHD were independently associated with inferior OS. In patients with malignant disease, both severe aGVHD and moderate/severe cGVHD were associated with increased risk of TRM. In conclusion, risk of moderate/severe cGVHD increases with recipient age, and risk of severe aGVHD is increased among older patients with nonmalignant conditions. Despite the low overall incidence of aGVHD and cGVHD in children, both are associated with significantly worse survival. These data highlight the need to consider GVHD outcomes at time of consultation and for improved prevention and treatment approaches.
- 24 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2108-2121
Open AccessImpact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients
Advances in graft-versus-host disease (GVHD) prevention and treatment have resulted in expanded donor options and improvement in treatment-related mortality (TRM). This analysis aimed to compare the incidence of acute and chronic GVHD (aGVHD and cGVHD, respectively) in pediatric patients by recipient age and to evaluate the impact of GVHD on overall survival (OS) and TRM. We included 14 099 patients aged ≤21 years who received their first allogeneic hematopoietic cell transplantation from 2002 to 2020, categorizing recipient age as 0 to 2 years (infants/toddlers), 3 to 12 years (school-aged), and 13 to 21 years (adolescent/young adult). There was no difference in grade 2 to 4 and 3 to 4 aGVHD by day 100 among age groups, except among patients with nonmalignant disease (NMD), among whom there was a small increase in incidence of severe aGVHD in older patients. Incidence of moderate/severe cGVHD by 1 year was higher with age. A similar impact of age was observed after adjusting for patient, donor, and transplant characteristics. Risk of severe aGVHD was higher in older children with NMD. Severe aGVHD and moderate/severe cGVHD were independently associated with inferior OS. In patients with malignant disease, both severe aGVHD and moderate/severe cGVHD were associated with increased risk of TRM. In conclusion, risk of moderate/severe cGVHD increases with recipient age, and risk of severe aGVHD is increased among older patients with nonmalignant conditions. Despite the low overall incidence of aGVHD and cGVHD in children, both are associated with significantly worse survival. These data highlight the need to consider GVHD outcomes at time of consultation and for improved prevention and treatment approaches.
- Open Access
- 29 August 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (17) , 4448-4457
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
Severe aplastic anemia (SAA) is a rare and life-threatening bone marrow failure disorder. Immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporine has long been a frontline treatment option in SAA; however, its limited durability and risk of long-term complications such as secondary malignancies remain a drawback in this treatment modality. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option with significantly improved outcomes over the long term, particularly with HLA-matched related donors. However, the use of alternative donors, such as haploidentical, mismatched, or matched unrelated donors, has previously been limited due to increased transplant-related morbidity, particularly graft-versus-host disease (GVHD). HCTs have therefore been limited to young recipients and those with HLA-matched related donors, creating significant disparity for older adults and those who lack matched donor options. Nevertheless, more recent advances in HCT, such as posttransplant cyclophosphamide for GVHD prophylaxis, have led to improved outcomes of HCT with alternative donors; however, alternative donor HCT remains underused as up-front therapy, in part because of limited multicenter trial data. This review discusses current SAA treatment approaches, including both IST and HCT, and highlights remaining gaps. It also discusses how ongoing clinical trials such as CureAA and TransIT could help address these gaps. Furthermore, we discuss the importance of stakeholder engagement and implementation science in the integration of research-based evidence into clinical practice. Bridging these gaps is necessary for achieving equitable access for patients historically excluded from frontline HCT, including older adults and racially or ethnically diverse populations.
- 29 August 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (17) , 4448-4457
Open AccessUp-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
Severe aplastic anemia (SAA) is a rare and life-threatening bone marrow failure disorder. Immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporine has long been a frontline treatment option in SAA; however, its limited durability and risk of long-term complications such as secondary malignancies remain a drawback in this treatment modality. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option with significantly improved outcomes over the long term, particularly with HLA-matched related donors. However, the use of alternative donors, such as haploidentical, mismatched, or matched unrelated donors, has previously been limited due to increased transplant-related morbidity, particularly graft-versus-host disease (GVHD). HCTs have therefore been limited to young recipients and those with HLA-matched related donors, creating significant disparity for older adults and those who lack matched donor options. Nevertheless, more recent advances in HCT, such as posttransplant cyclophosphamide for GVHD prophylaxis, have led to improved outcomes of HCT with alternative donors; however, alternative donor HCT remains underused as up-front therapy, in part because of limited multicenter trial data. This review discusses current SAA treatment approaches, including both IST and HCT, and highlights remaining gaps. It also discusses how ongoing clinical trials such as CureAA and TransIT could help address these gaps. Furthermore, we discuss the importance of stakeholder engagement and implementation science in the integration of research-based evidence into clinical practice. Bridging these gaps is necessary for achieving equitable access for patients historically excluded from frontline HCT, including older adults and racially or ethnically diverse populations.
- Open Access
- 1 August 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (8) , e2528882
Work Status, Absenteeism, Presenteeism, and Quality of Life in Young Adult Cancer Survivors
Importance: Current literature lacks information on the association between the work status and performance of young adult cancer survivors and their quality of life (QOL).Objective: To assess self-reported work status, missed time at work (absenteeism), and performance (presenteeism) and their associations with QOL among young adult cancer survivors.Design, Setting, and Participants: This cross-sectional survey study was performed from October 18, 2020, to September 17, 2022, at a single cancer center in Seattle, Washington. Participants included young adult cancer survivors (aged 18 to 39 years at diagnosis) who were 1 year or more from completion of cancer therapy. Data were analyzed from May 1, 2023, to February 1, 2025.Exposures: Cancer therapy.Main Outcomes and Measures: Unemployment rate compared with the age-, sex-, and calendar year–matched general population; standardized absolute and relative absenteeism and presenteeism scores; standardized scores for domains of anxiety, depression, physical function, fatigue, sleep disturbance, pain, social role, and cognition; and adjusted linear regressions to study factors associated with higher QOL scores.Results: A total of 198 survivors, with a median age at diagnosis of 31 (IQR, 26-35) years and a median age at survey of 39 (IQR, 35-44) years were included (142 [71.7%] female). The unemployment rate (14 [7.1%]) did not differ from that of the general population (4.7%) (P = .13). Compared with employed survivors, unemployed survivors reported significantly higher depression scores (coefficient, 5.11; 95% CI, 0.92-9.30) and lower scores for satisfaction with social roles and activities (coefficient, −6.59; 95% CI, −11.34 to −1.84) and physical function (coefficient, −6.63; 95% CI, −11.38 to −1.87). Higher absolute presenteeism score was associated with lower scores for anxiety (coefficient, −0.19; 95% CI, −0.26 to −0.11), depression (coefficient, −0.17; 95% CI, −0.24 to −0.10), fatigue (coefficient, −0.20; 95% CI, −0.30 to −0.10), pain interference (coefficient, −0.11; 95% CI, −0.21 to −0.02), and sleep disturbance (coefficient, −0.12; 95% CI, −0.21 to −0.03) and higher scores for physical function (coefficient, 0.08; 95% CI, 0.008-0.17), cognitive function (coefficient, 0.19; 95% CI, 0.11-0.27), and satisfaction in social roles and activities scores (coefficient, 0.16; 95% CI, 0.08-0.24). Additionally, a higher absolute absenteeism score was associated with a higher anxiety (coefficient, 0.03; 95% CI, 0.004-0.07) and lower cognitive function (coefficient, −0.04; 95% CI, −0.07 to −0.004).Conclusions and Relevance: In this cross-sectional study of young adult cancer survivors, associations were found between survivors’ self-reported work status and performance and their QOL affecting their mental, physical, and social health. These findings call for the development of effective communication strategies with employers to balance work expectations with survivors’ treatment-related complications to achieve better performance and in turn higher QOL.
- 1 August 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (8) , e2528882
Open AccessWork Status, Absenteeism, Presenteeism, and Quality of Life in Young Adult Cancer Survivors
Importance: Current literature lacks information on the association between the work status and performance of young adult cancer survivors and their quality of life (QOL).Objective: To assess self-reported work status, missed time at work (absenteeism), and performance (presenteeism) and their associations with QOL among young adult cancer survivors.Design, Setting, and Participants: This cross-sectional survey study was performed from October 18, 2020, to September 17, 2022, at a single cancer center in Seattle, Washington. Participants included young adult cancer survivors (aged 18 to 39 years at diagnosis) who were 1 year or more from completion of cancer therapy. Data were analyzed from May 1, 2023, to February 1, 2025.Exposures: Cancer therapy.Main Outcomes and Measures: Unemployment rate compared with the age-, sex-, and calendar year–matched general population; standardized absolute and relative absenteeism and presenteeism scores; standardized scores for domains of anxiety, depression, physical function, fatigue, sleep disturbance, pain, social role, and cognition; and adjusted linear regressions to study factors associated with higher QOL scores.Results: A total of 198 survivors, with a median age at diagnosis of 31 (IQR, 26-35) years and a median age at survey of 39 (IQR, 35-44) years were included (142 [71.7%] female). The unemployment rate (14 [7.1%]) did not differ from that of the general population (4.7%) (P = .13). Compared with employed survivors, unemployed survivors reported significantly higher depression scores (coefficient, 5.11; 95% CI, 0.92-9.30) and lower scores for satisfaction with social roles and activities (coefficient, −6.59; 95% CI, −11.34 to −1.84) and physical function (coefficient, −6.63; 95% CI, −11.38 to −1.87). Higher absolute presenteeism score was associated with lower scores for anxiety (coefficient, −0.19; 95% CI, −0.26 to −0.11), depression (coefficient, −0.17; 95% CI, −0.24 to −0.10), fatigue (coefficient, −0.20; 95% CI, −0.30 to −0.10), pain interference (coefficient, −0.11; 95% CI, −0.21 to −0.02), and sleep disturbance (coefficient, −0.12; 95% CI, −0.21 to −0.03) and higher scores for physical function (coefficient, 0.08; 95% CI, 0.008-0.17), cognitive function (coefficient, 0.19; 95% CI, 0.11-0.27), and satisfaction in social roles and activities scores (coefficient, 0.16; 95% CI, 0.08-0.24). Additionally, a higher absolute absenteeism score was associated with a higher anxiety (coefficient, 0.03; 95% CI, 0.004-0.07) and lower cognitive function (coefficient, −0.04; 95% CI, −0.07 to −0.004).Conclusions and Relevance: In this cross-sectional study of young adult cancer survivors, associations were found between survivors’ self-reported work status and performance and their QOL affecting their mental, physical, and social health. These findings call for the development of effective communication strategies with employers to balance work expectations with survivors’ treatment-related complications to achieve better performance and in turn higher QOL.
- 10 June 2025
- Published by Springer Nature
- Vol. 1475, 209-226
Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era
With the constantly changing field of hematopoietic cell transplant (HCT) and cellular therapy and a growing number of survivors, there is an ongoing need for work to understand the changing landscape of late effects and develop interventions to optimize the long-term outcomes of survivors. In this chapter, we summarize the studies published in last 5 years describing late effects after HCT. We specifically discuss the available literature or the lack thereof for the late effects as it relates to the changes in transplant practices such as increased use of post-transplant cyclophosphamide, newer drugs to treat chronic graft vs. host disease, and chimeric antigen receptor T-cell therapy as a bridge to HCT or for a post-HCT relapse. We also summarize the recently updated recommendations for screening and management of late effects and a monitoring plan to cater to late effects specific to patients undergoing transplants for non-malignant diseases. We discuss the specific considerations such as challenges for adolescent and young adult HCT survivors, especially as they transition from pediatric to adult care. With the information discussed here, we outline challenges and opportunities for research and clinical practice highlighting the role of health care delivery models in addressing some of these issues.
- 10 June 2025
- Published by Springer Nature
- Vol. 1475, 209-226
Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era
With the constantly changing field of hematopoietic cell transplant (HCT) and cellular therapy and a growing number of survivors, there is an ongoing need for work to understand the changing landscape of late effects and develop interventions to optimize the long-term outcomes of survivors. In this chapter, we summarize the studies published in last 5 years describing late effects after HCT. We specifically discuss the available literature or the lack thereof for the late effects as it relates to the changes in transplant practices such as increased use of post-transplant cyclophosphamide, newer drugs to treat chronic graft vs. host disease, and chimeric antigen receptor T-cell therapy as a bridge to HCT or for a post-HCT relapse. We also summarize the recently updated recommendations for screening and management of late effects and a monitoring plan to cater to late effects specific to patients undergoing transplants for non-malignant diseases. We discuss the specific considerations such as challenges for adolescent and young adult HCT survivors, especially as they transition from pediatric to adult care. With the information discussed here, we outline challenges and opportunities for research and clinical practice highlighting the role of health care delivery models in addressing some of these issues.
- Open Access
Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience
Background: Hematopoietic cell transplantation (HCT) remains the only curative therapy for pediatric myelodysplastic syndrome (MDS) in all but rare cases. While HCT outcomes for pediatric MDS are similar across the largest registry and single-center trials, factors identified as contributing to inferior outcomes vary from study to study. We performed an analysis to provide more clarity on the prognostic implications of disease characteristics, including blast burden and cytogenetic abnormalities, in the current era. Methods: We conducted a retrospective analysis of 36 consecutive children (p = 0.03). The inferior outcomes in patients with ≥5% blasts were due to increased relapse incidence (HR 7.6, CI 1.5–39.3) with no difference in NRM or acute GVHD. Conclusions: OS and RFS were comparable to what has been observed in other large, single-center studies (OS 77%, RFS 71% at 2 years) and compared favorably to outcomes from the largest multi-center retrospective analyses.
Open AccessDisease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience
Background: Hematopoietic cell transplantation (HCT) remains the only curative therapy for pediatric myelodysplastic syndrome (MDS) in all but rare cases. While HCT outcomes for pediatric MDS are similar across the largest registry and single-center trials, factors identified as contributing to inferior outcomes vary from study to study. We performed an analysis to provide more clarity on the prognostic implications of disease characteristics, including blast burden and cytogenetic abnormalities, in the current era. Methods: We conducted a retrospective analysis of 36 consecutive children (p = 0.03). The inferior outcomes in patients with ≥5% blasts were due to increased relapse incidence (HR 7.6, CI 1.5–39.3) with no difference in NRM or acute GVHD. Conclusions: OS and RFS were comparable to what has been observed in other large, single-center studies (OS 77%, RFS 71% at 2 years) and compared favorably to outcomes from the largest multi-center retrospective analyses.
- 21 August 2024
- Published by Springer Nature
- p. 327-342
Late Effects in Pediatric AML Survivors